Albuquerque, New Mexico and Basel, Switzerland – June 17, 2015 – Genedata and Intellicyt today announced an alliance that brings together the market-leading strengths of each company to transform screening of suspension cells. The technology alliance integrates the highly-scalable data analytics and workflow capabilities of Genedata Screener® software with the high-throughput (HT) flow cytometry capabilities of the Intellicyt iQue® Screener system. The integrated solution enables drug discovery researchers to efficiently screen large libraries against suspension cells and multiplex beads in phenotypic drug discovery, antibody screening, immunology, and biomarker research – an industry first.
Full Potential of Flow Cytometry -Realized
With the novel HT technology from Intellicyt built into the iQue Screener instrument, throughput in flow cytometry experiments is dramatically increased by 10-to 20-fold over other plate-based flow cytometry approaches. The Intellicyt iQue Screener system allows analysis of more than 10,000 cells or beads per second, each with 6 to 15 parameters, resulting in 60,000 to 150,000 data points per second from a given sample.
iQue Screener enables testing of over 36,000 low-volume, plate-based samples per day, with up to 15 parameters of information per cell. The challenge: efficient data analysis from the enormous data sets generated across all plates in screening experiments. Genedata software’s support of Intellicyt systems addresses this challenge with standardized data import options, highly scalable analysis workflows, and visualization strategies, all of which enable easy and objective interpretation of high-throughput flow cytometry data in screening experiments.
The Genedata/Intellicyt HT Flow Cytometry Solution
“Advanced computational analysis solutions are required to handle the quantity and complexity of data obtained in high-throughput flow cytometry experiments in large scale screening applications,” noted Janette Phi, chief business officer at Intellicyt. “The combined solution of Genedata Screener software and the Intellicyt iQue Screener platform addresses this unmet industry need. Our solution provides a powerful option for our customers for robust and accurate data analysis across all plates from high-throughput flow cytometry data generated by iQue.”
Intellicyt iQue Screener is an integrated instrument, software, and reagent system that enables rapid, high content, multiplexed analysis of cells and beads in suspension in industry standard 96-, 384-, or 1536-well plates. iQue Screener combines a powerful flow cytometry detection engine with a novel, patented, rapid sampling technology that minimizes sample and reagent usage while maximizing the speed of sample analysis. Sample volumes of 1 microliter are typical and a 384-well plate can be analyzed in 12 minutes. The resulting data can then be easily moved to Genedata Screener software for further advanced data analysis, providing insight into complex biology across multiple plates, which is needed in large screening campaigns.
Genedata Screener, the de facto standard for all plate-based screening, imports well results for any size campaign and supports fast and efficient processing of routine screening. In addition to well data, it imports raw and pre-gated cell data from Intellicyt iQue systems. This allows drill-down from well results to the underlying cell populations, enabling researchers to adjust and optimize the cell-to-well aggregation in the context of a complete campaign.
Supporting the FCS3 data file standard, the Genedata/Intellicyt solution delivers all the data analysis benefits of Genedata software combined with the speed and efficiency of Intellicyt iQue systems, enabling:
- Easy import of interactive analysis of 15 or more result parameters across a complete screening campaign for all screening applications including dose response curve fitting.
- Optional import of cell data for in-depth QC from wells to cell populations and back.
- Overall reduction of data analysis time by extending the built-in support for screening to the HT flow technology.
- Reduced errors and enhanced data quality results.
- Removal of human bias with standardized workflows.
- Integration of HT flow technology into the regular screening workflow for results reporting from HT flow directly to the data warehouse without additional integration of data processing pipelines.
“The alliance between Genedata and Intellicyt underscores our commitment to support all emerging technologies that drive value for our customers,” said Dr. Othmar Pfannes, CEO of Genedata. “It’s especially exciting to see a screening technology mature and scale to high throughput and that Genedata Screener easily supports yet another technology that empowers researchers to quickly interpret flow cytometry results and optimize result quality.”
Intellicyt produces innovative tools that facilitate the study of cells, and the components of cells, to gain a better understanding of normal and disease processes. This information is used to revolutionize the discovery and development of new drugs and to provide new insight into the diagnosis of diseases. Intellicyt was the first to commercialize a true high throughput, cell-based screening platform optimized for suspension cells and multiplex beads. Intellicyt instrumentation, software, and reagent products are used worldwide throughout pharmaceutical, biotechnology, and life science research organizations.
Genedata transforms data into intelligence with a portfolio of advanced software solutions, which make research data accessible and understandable and research processes more efficient. These solutions are used worldwide by leading pharmaceutical, industrial, and agricultural biotechnology companies as well as academic research organizations. Genedata innovations enable scientific discovery that fights disease and improves health and quality of life worldwide. Founded in 1997, Genedata is headquartered in Switzerland, and has offices in Germany, Japan, and the US.
Genedata Screener Public Relations
+1 508 380 6408
Click here to contact Intellicyt.
The statements in this press release that relate to future plans, events, or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company’s products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.